Trump's trade dispute impacts German pharma revenue
German pharmaceutical industry anticipates a 2.2% decline in production and a 1.8% decrease in real revenue during 2026 due to trade disputes with the United States and Trump's threat to impose tariffs of up to 100%. Additionally, sector investments, which employ around 130,000 people, will decrease as challenges stemming from austerity measures and manufacturer discounts persist. The trade conflict has led to a reduction in exports and production to the U.S., despite companies like Merck having previously invested billions of dollars there. Companies are also facing additional burdens from government discounts, with the expectation that investments and research expenditures will decline by more than 4 billion euros by 2030.
Notice: This Is an AI-Generated Summary
Comments (0)